VolitionRX Ltd (VNRX)

Mar 13, 2025

VolitionRx expands cancer test deal with Fujifilm Vet Systems By Investing.com - Investing.com Australia

Mar 13, 2025

Mar 13, 2025

VolitionRx extends Nu.Q Vet Cancer Test automation agreement with Fujifilm - TipRanks

Mar 13, 2025

Mar 13, 2025

Volition Signs First Ever Nu.Q Vet Cancer Test Automation Agreement With Fujifilm Vet Systems - Marketscreener.com

Mar 13, 2025

Mar 13, 2025

VolitionRx Signs Canine Cancer Test Automation Deal With Fujifilm Vet Systems -March 13, 2025 at 09:07 am EDT - Marketscreener.com

Mar 13, 2025

Mar 13, 2025

Volition's Game-Changing Cancer Test for Dogs Goes Automated with Fujifilm Deal - StockTitan

Mar 13, 2025

Mar 12, 2025

StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX) - Defense World

Mar 12, 2025

Mar 05, 2025

VNRX: Additional clinical papers & company webinars provide insights to Volition’s progress. Nu.Q Discover biomarkers selected for clinical trial. Management continues to focus on signing licensing deals for Capture-PCR & Nu.Q NETs - Yahoo Finance

Mar 05, 2025

Mar 05, 2025

VolitionRx’s (VNRX) Buy Rating Reaffirmed at D. Boral Capital - Defense World

Mar 05, 2025

Mar 04, 2025

Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time - Yahoo Finance

Mar 04, 2025

Mar 04, 2025

VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com - Defense World

Mar 04, 2025

Feb 27, 2025

VolitionRX Ltd. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025

Feb 24, 2025

VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com - Defense World

Feb 24, 2025

Feb 17, 2025

Examining the Potential Price Growth of VolitionRX Ltd (VNRX) - Knox Daily

Feb 17, 2025

Feb 12, 2025

Analyzing IDEXX Laboratories (NASDAQ:IDXX) and VolitionRx (NYSE:VNRX) - Defense World

Feb 12, 2025

Feb 07, 2025

VolitionRX Ltd (VNRX) Shares Up Despite Recent Market Volatility - The News Heater

Feb 07, 2025

Feb 05, 2025

Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025 - Yahoo Finance

Feb 05, 2025

Jan 30, 2025

Game-Changing Sepsis Detection: 971-Patient Study Validates Revolutionary Blood Test - StockTitan

Jan 30, 2025

Jan 21, 2025

Inflammatix’s Triverity scores FDA clearance for ER sepsis test - BioWorld Online

Jan 21, 2025

Jan 15, 2025

Veterinary Oncology Diagnostics Market Size Report, 2030 - Grand View Research

Jan 15, 2025

Jan 10, 2025

D. Boral Capital Reiterates Buy Rating for VolitionRx (NYSE:VNRX) - Defense World

Jan 10, 2025

Jan 08, 2025

VolitionRx reports expanded global reach in 2024 - Investing.com India

Jan 08, 2025

Jan 08, 2025

VolitionRx's Nu.Q® Vet Cancer Test Hits Major Milestone: 110,000+ Tests Sold Across 20 Countries - StockTitan

Jan 08, 2025

Dec 27, 2024

Competition ticks up to reset the clock for sepsis - BioWorld Online

Dec 27, 2024

Dec 22, 2024

VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com - Defense World

Dec 22, 2024

Dec 11, 2024

VolitionRx CEO Cameron John Reynolds acquires $79,999 in stock By Investing.com - Investing.com Nigeria

Dec 11, 2024

Dec 10, 2024

Volitionrx director Innes buys $99,999 in common stock By Investing.com - Investing.com Australia

Dec 10, 2024

Dec 10, 2024

Volitionrx director Innes buys $99,999 in common stock - Investing.com India

Dec 10, 2024

Dec 10, 2024

VolitionRx chief scientific officer Micallef acquires $24,999 in stock By Investing.com - Investing.com Australia

Dec 10, 2024

Dec 10, 2024

VolitionRx CEO Cameron John Reynolds acquires $79,999 in stock - Investing.com

Dec 10, 2024

Dec 09, 2024

SEC Form 424B5 filed by VolitionRX Limited - Quantisnow

Dec 09, 2024

Dec 09, 2024

Form 424B5 VOLITIONRX LTD - StreetInsider.com

Dec 09, 2024

Dec 09, 2024

VolitionRx announces pricing of up to $1.9M registered direct offering - MSN

Dec 09, 2024

Dec 06, 2024

VolitionRx announces $1.9 million stock sale By Investing.com - Investing.com Australia

Dec 06, 2024

Dec 06, 2024

VolitionRx Secures $1.9M Financing with Insider Backing, Includes Strategic Warrant Package - StockTitan

Dec 06, 2024

Dec 04, 2024

VNRX: VolitionRx Reports 3Q 2024 results. Over 110,000 Nu.Q Canine Cancer tests have been sold. Cost cutting continues in a plan to be cash flow neutral in 2025. Management focused on signing licensing deals for Capture-PCR & Nu.Q NETs. - Zacks Small Cap Research

Dec 04, 2024

Dec 02, 2024

VolitionRx: Big EU Trials On Deck - Investing.com

Dec 02, 2024

Nov 28, 2024

VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com - Defense World

Nov 28, 2024

Nov 23, 2024

Benchmark Reaffirms Hold Rating for VolitionRx (NYSE:VNRX) - MarketBeat

Nov 23, 2024

Nov 20, 2024

VolitionRx Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 20, 2024

Nov 16, 2024

VolitionRx Limited (AMEX:VNRX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 16, 2024

Nov 16, 2024

VolitionRX: Q3 Earnings Snapshot - New Haven Register

Nov 16, 2024

Nov 16, 2024

VolitionRX Ltd (VNRX) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance

Nov 16, 2024

Nov 15, 2024

VolitionRx Posts Strong Q3 Growth and Strategic Advances - TipRanks

Nov 15, 2024

Nov 15, 2024

Lagoda Investment Management's Strategic Acquisition in Volition - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Armistice Capital, LLC Acquires New Stake in VolitionRX Ltd - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

VolitionRX Ltd Reports Q3 Revenue of $475,000, Missing Estimates of $0.65 Million - GuruFocus.com

Nov 14, 2024